

CERVICAL CANCER SCREENING

VOLUME 18

This publication represents the views and expert opinions of an IARC Working Group on the Evaluation of Cancer-Preventive Interventions, which met remotely, 12–16 October 2020

LYON, FRANCE - 2022

IARC HANDBOOKS OF
CANCER PREVENTION

References

- Agorastos T, Chatzistamatiou K, Katsamagkas T, Koliopoulos G, Daponte A, Constantinidis T, et al.; HERMES study group (2015). Primary screening for cervical cancer based on high-risk human papillomavirus (HPV) detection and HPV 16 and HPV 18 genotyping, in comparison to cytology. *PLoS One*. 10(3):e0119755. doi:[10.1371/journal.pone.0119755](https://doi.org/10.1371/journal.pone.0119755) PMID:[25793281](https://pubmed.ncbi.nlm.nih.gov/25793281/)
- Agorastos T, Chatzistamatiou K, Moysiadis T, Kaufmann AM, Skenderi A, Lekka I, et al. (2017). Human papillomavirus E7 protein detection as a method of triage to colposcopy of HPV positive women, in comparison to genotyping and cytology. Final results of the PIPAVIR study. *Int J Cancer*. 141(3):519–30. doi:[10.1002/ijc.30761](https://doi.org/10.1002/ijc.30761) PMID:[28470689](https://pubmed.ncbi.nlm.nih.gov/28470689/)
- Asthana S, Labani S (2015). Adjunct screening of cervical or vaginal samples using careHPV testing with Pap and aided visual inspection for detecting high-grade cervical intraepithelial neoplasia. *Cancer Epidemiol*. 39(1):104–8. doi:[10.1016/j.canep.2014.11.006](https://doi.org/10.1016/j.canep.2014.11.006) PMID:[25548076](https://pubmed.ncbi.nlm.nih.gov/25548076/)
- Bian ML, Cheng JY, Ma L, Cong X, Liu J, Chen Y, et al. (2013). Evaluation of the detection of 14 high-risk human papillomaviruses with HPV 16 and HPV 18 genotyping for cervical cancer screening. *Exp Ther Med*. 6(5):1332–6. doi:[10.3892/etm.2013.1309](https://doi.org/10.3892/etm.2013.1309) PMID:[24223668](https://pubmed.ncbi.nlm.nih.gov/24223668/)
- Castle PE, Stoler MH, Wright TC Jr, Sharma A, Wright TL, Behrens CM (2011). Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. *Lancet Oncol*. 12(9):880–90. doi:[10.1016/S1470-2045\(11\)70188-7](https://doi.org/10.1016/S1470-2045(11)70188-7) PMID:[21865084](https://pubmed.ncbi.nlm.nih.gov/21865084/)
- Chao A, Hsu KH, Lai CH, Huang HJ, Hsueh S, Lin SR, et al. (2008). Cervical cancer screening program integrating Pap smear and HPV DNA testing: a population-based study. *Int J Cancer*. 122(12):2835–41. doi:[10.1002/ijc.23441](https://doi.org/10.1002/ijc.23441) PMID:[18338752](https://pubmed.ncbi.nlm.nih.gov/18338752/)
- Confortini M, Giorgi Rossi P, Barbarino P, Passarelli AM, Orzella L, Tufi MC (2010). Screening for cervical cancer with the human papillomavirus test in an area of central Italy with no previous active cytological screening programme. *J Med Screen*. 17(2):79–86. doi:[10.1258/jms.2010.009092](https://doi.org/10.1258/jms.2010.009092) PMID:[20660436](https://pubmed.ncbi.nlm.nih.gov/20660436/)
- Cook DA, Smith LW, Law J, Mei W, van Niekerk DJ, Ceballos K, et al. (2017). Aptima HPV Assay versus Hybrid Capture® 2 HPV test for primary cervical cancer screening in the HPV FOCAL trial. *J Clin Virol*. 87:23–9. doi:[10.1016/j.jcv.2016.12.004](https://doi.org/10.1016/j.jcv.2016.12.004) PMID:[27988420](https://pubmed.ncbi.nlm.nih.gov/27988420/)
- Depetrini E, Bonelli L, Ardoino S, Cirucca MC, Contin R, De Leonardis D, et al. (2016). Cervical cancer screening with primary HPV-DNA test in the Local Health Authority 2 of Savona (Liguria Region, Northern Italy): a population-based study. [in Italian] *Epidemiol Prev*. 40(3–4):171–8. doi:[10.19191/EP16.3-4.AD04.078](https://doi.org/10.19191/EP16.3-4.AD04.078) PMID:[27436250](https://pubmed.ncbi.nlm.nih.gov/27436250/)
- Ferreccio C, Barriga MI, Lagos M, Ibáñez C, Poggi H, González F, et al. (2013). Screening trial of human papillomavirus for early detection of cervical cancer in Santiago, Chile. *Int J Cancer*. 132(4):916–23. doi:[10.1002/ijc.27662](https://doi.org/10.1002/ijc.27662) PMID:[22684726](https://pubmed.ncbi.nlm.nih.gov/22684726/)
- Guo M, Khanna A, Feng J, Patel S, Zhang W, Gong Y, et al. (2015). Analytical performance of Cervista HPV 16/18 in SurePath Pap specimens. *Diagn Cytopathol*. 43(4):301–6. doi:[10.1002/dc.23221](https://doi.org/10.1002/dc.23221) PMID:[25352375](https://pubmed.ncbi.nlm.nih.gov/25352375/)
- Gustinucci D, Giorgi Rossi P, Cesarini E, Broccolini M, Bulletti S, Cariani A, et al. (2016). Use of cytology, E6/E7 mRNA, and p16^{INK4a}-Ki-67 to define the management of human papillomavirus (HPV)-positive women in cervical cancer screening. *Am J Clin Pathol*. 145(1):35–45. doi:[10.1093/ajcp/aqv019](https://doi.org/10.1093/ajcp/aqv019) PMID:[26712869](https://pubmed.ncbi.nlm.nih.gov/26712869/)
- Isidean SD, Mayrand MH, Ramanakumar AV, Rodrigues I, Ferenczy A, Ratnam S, et al.; CCCaST Study Group (2017). Comparison of triage strategies for HPV-positive women: Canadian Cervical Cancer Screening Trial results. *Cancer Epidemiol Biomarkers Prev*. 26(6):923–9. doi:[10.1158/1055-9965.EPI-16-0705](https://doi.org/10.1158/1055-9965.EPI-16-0705) PMID:[28096198](https://pubmed.ncbi.nlm.nih.gov/28096198/)
- Kocsis A, Takács T, Jeney C, Schaff Z, Koiss R, Járay B, et al. (2017). Performance of a new HPV and biomarker assay in the management of hrHPV positive women: subanalysis of the ongoing multicenter TRACE clinical trial ($n > 6,000$) to evaluate POU4F3 methylation as a potential biomarker of cervical precancer and cancer. *Int J Cancer*. 140(5):1119–33. doi:[10.1002/ijc.30534](https://doi.org/10.1002/ijc.30534) PMID:[27874187](https://pubmed.ncbi.nlm.nih.gov/27874187/)
- Leinonen MK, Anttila A, Malila N, Dillner J, Forslund O, Nieminen P (2013). Type- and age-specific distribution of human papillomavirus in women attending cervical cancer screening in Finland. *Br J Cancer*. 109(11):2941–50. doi:[10.1038/bjc.2013.647](https://doi.org/10.1038/bjc.2013.647) PMID:[24136148](https://pubmed.ncbi.nlm.nih.gov/24136148/)
- Liu M, Yan X, Zhang M, Li X, Li S, Jing M (2017). Influence of human papillomavirus infection on the natural history of cervical intraepithelial neoplasia 1: a meta-analysis. *BioMed Res Int*. 2017:8971059. doi:[10.1155/2017/8971059](https://doi.org/10.1155/2017/8971059) PMID:[28812024](https://pubmed.ncbi.nlm.nih.gov/28812024/)
- Luo H, Du H, Belinson JL, Wu R (2019). Evaluation of alternately combining HPV viral load and 16/18 genotyping in secondary screening algorithms. *PLoS One*. 14(7):e0220200. doi:[10.1371/journal.pone.0220200](https://doi.org/10.1371/journal.pone.0220200) PMID:[31348794](https://pubmed.ncbi.nlm.nih.gov/31348794/)
- Maggino T, Sciarrone R, Murer B, Dei Rossi MR, Fedato C, Maran M, et al. (2016). Screening women for cervical cancer carcinoma with a HPV mRNA test: first results from the Venice pilot program. *Br J Cancer*. 115(5):525–32. doi:[10.1038/bjc.2016.216](https://doi.org/10.1038/bjc.2016.216) PMID:[27490801](https://pubmed.ncbi.nlm.nih.gov/27490801/)
- Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, et al.; Canadian Cervical Cancer Screening Trial Study Group (2007). Human

- papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. *N Engl J Med.* 357(16):1579–88. doi:[10.1056/NEJMoa071430](https://doi.org/10.1056/NEJMoa071430) PMID:[17942871](https://pubmed.ncbi.nlm.nih.gov/17942871/)
- Muwonge R, Wesley RS, Nene BM, Shastri SS, Jayant K, Malvi SG, et al. (2014). Evaluation of cytology and visual triage of human papillomavirus-positive women in cervical cancer prevention in India. *Int J Cancer.* 134(12):2902–9. doi:[10.1002/ijc.28627](https://doi.org/10.1002/ijc.28627) PMID:[24272364](https://pubmed.ncbi.nlm.nih.gov/24272364/)
- Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Elfgrén K, et al. (2009). Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. *J Natl Cancer Inst.* 101(2):88–99. doi:[10.1093/jnci/djn444](https://doi.org/10.1093/jnci/djn444) PMID:[19141778](https://pubmed.ncbi.nlm.nih.gov/19141778/)
- Pan QJ, Hu SY, Guo HQ, Zhang WH, Zhang X, Chen W, et al. (2014). Liquid-based cytology and human papillomavirus testing: a pooled analysis using the data from 13 population-based cervical cancer screening studies from China. *Gynecol Oncol.* 133(2):172–9. doi:[10.1016/j.ygyno.2014.03.008](https://doi.org/10.1016/j.ygyno.2014.03.008) PMID:[24631450](https://pubmed.ncbi.nlm.nih.gov/24631450/)
- Pasquale L, Giorgi Rossi P, Carozzi F, Pedretti C, Ruggeri C, Scalvinoni V, et al. (2015). Cervical cancer screening with HPV testing in the Valcamonica (Italy) screening programme. *J Med Screen.* 22(1):38–48. doi:[10.1177/0969141314561707](https://doi.org/10.1177/0969141314561707) PMID:[25431452](https://pubmed.ncbi.nlm.nih.gov/25431452/)
- Passamonti B, Gustinucci D, Giorgi Rossi P, Cesarini E, Bulletti S, Cariani A, et al. (2017). Cervical human papilloma virus (HPV) DNA primary screening test: results of a population-based screening programme in central Italy. *J Med Screen.* 24(3):153–62. doi:[10.1177/0969141316663580](https://doi.org/10.1177/0969141316663580) PMID:[27614992](https://pubmed.ncbi.nlm.nih.gov/27614992/)
- Petry KU, Menton S, Menton M, van Loenen-Frosch F, de Carvalho Gomes H, Holz B, et al. (2003). Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients. *Br J Cancer.* 88(10):1570–7. doi:[10.1038/sj.bjc.6600918](https://doi.org/10.1038/sj.bjc.6600918) PMID:[12771924](https://pubmed.ncbi.nlm.nih.gov/12771924/)
- Rebolj M, Bonde J, Ejegod D, Preisler S, Rygaard C, Lynge E (2015). A daunting challenge: human papillomavirus assays and cytology in primary cervical screening of women below age 30 years. *Eur J Cancer.* 51(11):1456–66. doi:[10.1016/j.ejca.2015.04.012](https://doi.org/10.1016/j.ejca.2015.04.012) PMID:[25979832](https://pubmed.ncbi.nlm.nih.gov/25979832/)
- Rezhake R, Hu SY, Zhao S, Xu XQ, Zhao XL, Zhang L, et al. (2019). Eight-type human papillomavirus E6/E7 oncoprotein detection as a novel and promising triage strategy for managing HPV-positive women. *Int J Cancer.* 144(1):34–42. doi:[10.1002/ijc.31633](https://doi.org/10.1002/ijc.31633) PMID:[29943809](https://pubmed.ncbi.nlm.nih.gov/29943809/)
- Rijkaart DC, Berkhof J, van Kemenade FJ, Coupe VM, Hesselink AT, Rozendaal L, et al. (2012). Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening. *Int J Cancer.* 130(3):602–10. doi:[10.1002/ijc.26056](https://doi.org/10.1002/ijc.26056) PMID:[21400507](https://pubmed.ncbi.nlm.nih.gov/21400507/)
- Ronco G, Giorgi-Rossi P, Carozzi F, Dalla Palma P, Del Mistro A, De Marco L, et al.; New Technologies for Cervical Cancer Screening Working Group (2006a). Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. *Lancet Oncol.* 7(7):547–55. doi:[10.1016/S1470-2045\(06\)70731-8](https://doi.org/10.1016/S1470-2045(06)70731-8) PMID:[16814206](https://pubmed.ncbi.nlm.nih.gov/16814206/)
- Ronco G, Segnan N, Giorgi-Rossi P, Zappa M, Casadei GP, Carozzi F, et al.; New Technologies for Cervical Cancer Working Group (2006b). Human papillomavirus testing and liquid-based cytology: results at recruitment from the New Technologies for Cervical Cancer randomized controlled trial. *J Natl Cancer Inst.* 98(11):765–74. doi:[10.1093/jnci/djj209](https://doi.org/10.1093/jnci/djj209) PMID:[16757701](https://pubmed.ncbi.nlm.nih.gov/16757701/)
- Sangrajrang S, Laowahutanont P, Wongsena M, Muwonge R, Karalak A, Imsamran W, et al. (2017). Comparative accuracy of Pap smear and HPV screening in Ubon Ratchathani in Thailand. *Papillomavirus Res.* 3:30–5. doi:[10.1016/j.pvr.2016.12.004](https://doi.org/10.1016/j.pvr.2016.12.004) PMID:[28720454](https://pubmed.ncbi.nlm.nih.gov/28720454/)
- Siraiangkul S, Settakorn J, Sukpan K, Srisomboon J, Suprasert P, Kasatpibal N, et al. (2014). Population-based cervical cancer screening using high-risk HPV DNA test and liquid-based cytology in northern Thailand. *Asian Pac J Cancer Prev.* 15(16):6837–42. doi:[10.7314/APJCP.2014.15.16.6837](https://doi.org/10.7314/APJCP.2014.15.16.6837) PMID:[25169534](https://pubmed.ncbi.nlm.nih.gov/25169534/)
- Stanczuk GA, Baxter GJ, Currie H, Forson W, Lawrence JR, Cuschieri K, et al. (2017). Defining optimal triage strategies for hrHPV screen-positive women – an evaluation of HPV 16/18 genotyping, cytology, and p16/Ki-67 cytoimmunochemistry. *Cancer Epidemiol Biomarkers Prev.* 26(11):1629–35. doi:[10.1158/1055-9965.EPI-17-0534](https://doi.org/10.1158/1055-9965.EPI-17-0534) PMID:[28887297](https://pubmed.ncbi.nlm.nih.gov/28887297/)
- Terrazas S, Ibáñez C, Lagos M, Poggi H, Brañes J, Barriga MI, et al. (2015). Human papillomavirus testing in cervical cancer screening at a public health service of Santiago, Chile. [in Spanish] *Rev Med Chil.* 143(1):56–62. doi:[10.4067/S0034-98872015000100007](https://doi.org/10.4067/S0034-98872015000100007) PMID:[25860269](https://pubmed.ncbi.nlm.nih.gov/25860269/)
- Tian Q, Li Y, Wang F, Li Y, Xu J, Shen Y, et al. (2014). MicroRNA detection in cervical exfoliated cells as a triage for human papillomavirus-positive women. *J Natl Cancer Inst.* 106(9):dju241. doi:[10.1093/jnci/dju241](https://doi.org/10.1093/jnci/dju241) PMID:[25190727](https://pubmed.ncbi.nlm.nih.gov/25190727/)
- Torres-Ibarra L, Cuzick J, Lorincz AT, Spiegelman D, Lazcano-Ponce E, Franco EL, et al.; FRIDA Study Group (2019). Comparison of HPV-16 and HPV-18 genotyping and cytological testing as triage testing within human papillomavirus-based screening in Mexico. *JAMA Netw Open.* 2(11):e1915781. doi:[10.1001/jamanetworkopen.2019.15781](https://doi.org/10.1001/jamanetworkopen.2019.15781) PMID:[31747033](https://pubmed.ncbi.nlm.nih.gov/31747033/)
- Tshomo U, Franceschi S, Tshokey T, Tobgay T, Baussano I, Tenet V, et al. (2017). Evaluation of cytology versus human papillomavirus-based cervical cancer screening algorithms in Bhutan. *Oncotarget.* 8(42):72438–46. doi:[10.18632/oncotarget.19783](https://doi.org/10.18632/oncotarget.19783) PMID:[29069800](https://pubmed.ncbi.nlm.nih.gov/29069800/)
- Wentzensen N, Fetterman B, Castle PE, Schiffman M, Wood SN, Stiemerling E, et al. (2015). p16/Ki-67 dual stain cytology for detection of cervical precancer in

- HPV-positive women. *J Natl Cancer Inst.* 107(12):dju257. doi:[10.1093/jnci/dju257](https://doi.org/10.1093/jnci/dju257) PMID:[26376685](https://pubmed.ncbi.nlm.nih.gov/26376685/)
- Wu Q, Zhao X, Fu Y, Wang X, Zhang X, Tian X, et al. (2017). A cross-sectional study on HPV testing with type 16/18 genotyping for cervical cancer screening in 11,064 Chinese women. *Cancer Med.* 6(5):1091–101. doi:[10.1002/cam4.1060](https://doi.org/10.1002/cam4.1060) PMID:[28378404](https://pubmed.ncbi.nlm.nih.gov/28378404/)
- Zhang Y, Wang Y, Liu L, Guo C, Liu Z, Nie S (2016). Prevalence of human papillomavirus infection and genotyping for population-based cervical screening in developed regions in China. *Oncotarget.* 7(38):62411–24. doi:[10.18632/oncotarget.11498](https://doi.org/10.18632/oncotarget.11498) PMID:[27566561](https://pubmed.ncbi.nlm.nih.gov/27566561/)